Clinical Trials Logo

Filter by:
NCT ID: NCT05131295 Completed - Clinical trials for Subarachnoid Hemorrhage

Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.

Start date: September 5, 2007
Phase: Phase 3
Study type: Interventional

Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect, making it widely available. Its neuroprotective effects have been found through its glutamate receptors antagonistic effect. Their main objective was to study the neuroprotective properties in patients with aneurysmal subarachnoid hemorrhage and high-risk factors for the development of cerebral vasospasm. Both the placebo and the dapsone used in this clinical trial were provided by the institution's neurochemistry laboratory.

NCT ID: NCT05131087 Completed - Glaucoma Clinical Trials

A First-In-Human Clinical Trial to Evaluate the Safety, Effectiveness and Surgical Characteristics of CADENCE in Patients With Refractory Glaucoma

Start date: October 8, 2020
Phase: N/A
Study type: Interventional

To evaluate safety, effectiveness, and the surgical performance of CADENCE in patients with refractory glaucoma.

NCT ID: NCT05128344 Withdrawn - Spasms, Infantile Clinical Trials

A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

Start date: April 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of AMZ002 compared to Vigabatrin in participants with newly diagnosed infantile spasms (IS).

NCT ID: NCT05127434 Active, not recruiting - Clinical trials for Respiratory Syncytial Virus

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

Start date: November 17, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) as compared with placebo from 14 days postinjection through 12 months. The main purpose of Part B of this study is to evaluate the safety, tolerability and immunogenicity of a booster dose (BD) of mRNA-1345 administered 24 months after the primary dose.

NCT ID: NCT05126576 Suspended - COVID-19 Clinical Trials

Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19

MORNINGSKY
Start date: April 28, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting.

NCT ID: NCT05126277 Recruiting - Lupus Nephritis Clinical Trials

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

SIRIUS-LN
Start date: July 14, 2022
Phase: Phase 3
Study type: Interventional

This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN

NCT ID: NCT05124158 Completed - COVID-19 Clinical Trials

COVID-19 Severity and Psychiatric Morbidity

Start date: October 1, 2021
Phase:
Study type: Observational [Patient Registry]

The COVID-19 pandemic represents the most serious global health threat since the Spanish influenza, with repercussions on physical and mental health. The balance between physical and mental state is essential when establishing treatment for a critically ill patient and must be taken into account by health professionals. Therefore, the investigators hypothesize that there is an association between the severity of the clinical picture of COVID-19 and psychiatric morbidity. Objective. Associate the severity of the clinical picture of COVID-19 with psychiatric morbidity. Material and method. Hospitalized participants in the COVID respiratory area at the General Hospital of the Zone will be included. # 51 of Gómez Palacio, Dgo. in the period from October 1, 2021 to March 31, 2022. This is an epidemiological, observational, prospective, longitudinal, analytical study. Sociodemographic, clinical and psychiatric evaluation data will be obtained using GMHAT / PC. A statistical analysis will be carried out using descriptive statistics (frequencies, measures of central tendency and dispersion) and analytical, to evaluate the association (Chi2) and to evaluate the effect of the intervening variables (binary logistic regression and multivariate regression). The data will be analyzed in the SPSS version 21 program.

NCT ID: NCT05123703 Recruiting - Clinical trials for Relapsing-Remitting Multiple Sclerosis

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis

Operetta 2
Start date: February 4, 2022
Phase: Phase 3
Study type: Interventional

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.

NCT ID: NCT05123586 Completed - Clinical trials for Systemic Lupus Erythematosus

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

Start date: March 7, 2022
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits.

NCT ID: NCT05123573 Completed - COVID-19 Pandemic Clinical Trials

Self-Perceived in Medical Students Undergoing Distance Learning

SPMSUDL
Start date: October 19, 2021
Phase:
Study type: Observational

Our primary objective is identifying the degree of self-perceived competence in medical students without clinical rotations during the COVID-19 pandemic to know how prepared the students could be when they are professionals because they lack clinical skills in front of an actual patient and can be affected to be accepted in hospitals because they will have to acquire a phase of training later. Without a clinical rotation, one can be deprived of the essential educational value.The study design is an observational cross-section study in which an anonymous survey will be shared online on Google Forms platform. Students will be asked for their participation; after obtaining verbal and consent, the survey will be distributed using social media groups such as foundation school groups. For this study, the Spanish version of the Self-Perceived Competence scale will be used (REF). This scale is comprised of 21 questions divided into five factors that assess: 1) demonstration of the essential clinical skills, 2) demonstration of clinical reasoning, decision making, and problem-solving skills, 3) management of life-threatening medical conditions, 4) management of common medical problems and 5) placing patients' needs and safety at the center of the care process. Each item has a Likert scale answers of 4 options ranging from "incompetent (1)", "somewhat incompetent (2)", "somewhat.